AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients
Portfolio Pulse from Vandana Singh
AbbVie Inc (NYSE:ABBV) reported positive Phase 2 trial results for Teliso-V in treating a subtype of advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC) patients. The study showed an overall response rate of 35% in c-Met High and 23% in c-Met Intermediate patients, with median overall survival of 14.6 and 14.2 months, respectively. The safety profile was consistent with previous findings, and no new safety concerns were identified. AbbVie's stock rose 0.60% to $138.91.
November 29, 2023 | 6:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's Teliso-V shows encouraging results in Phase 2 NSCLC trial, with good response rates and survival times, and no new safety concerns.
The positive trial results are likely to be viewed favorably by investors, as they suggest potential for Teliso-V to become a successful treatment for NSCLC, which could lead to increased revenue for AbbVie. The lack of new safety concerns adds to the positive sentiment. The stock price increase on the day of the announcement indicates immediate market reaction.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100